MSC therapy for ankylosing spondylitis — immunomodulation and spinal inflammation reduction research

What Is Ankylosing Spondylitis?

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that primarily targets the axial skeleton — the sacroiliac joints and spine — driving a progressive cycle of inflammation, erosive damage, and pathological new bone formation that can ultimately fuse the vertebrae into a rigid, immobile structure. It belongs to the spondyloarthritis family and is strongly associated with the HLA-B27 gene, though the precise trigger remains incompletely understood [1].

AS affects approximately 0.1–1.4% of the global population, with onset typically between ages 20 and 40 — striking patients in the prime of their working lives. The hallmark symptom is inflammatory back pain: insidious in onset, worse with rest, improving with activity, and accompanied by prolonged morning stiffness lasting 30 minutes or more. Over time, uncontrolled inflammation leads to syndesmophyte formation, ankylosis of the sacroiliac joints, and the classic "bamboo spine" appearance on radiographs [2].

Biologics have transformed AS care but leave substantial unmet need. TNF inhibitors (adalimumab, infliximab, etanercept) and IL-17 inhibitors (secukinumab, ixekizumab) achieve clinically meaningful responses in 60–70% of patients, reducing pain and improving function. However, complete remission is rare — fewer than 25% achieve ASDAS inactive disease — and radiographic progression continues in a significant subset despite apparent clinical response [3]. Moreover, 20–30% of patients are primary non-responders or lose response over time, and biologics carry risks of serious infection, demyelination, and reactivation of latent tuberculosis.

MSC therapy targets the underlying inflammatory pathology differently. Rather than blocking a single cytokine, MSCs exert broad-spectrum immunomodulation, simultaneously suppressing multiple pathogenic pathways — Th17-driven inflammation, macrophage activation, osteoclast-mediated bone erosion — while secreting trophic factors that may protect chondrocytes and intervertebral disc cells from inflammatory damage [4].

How MSCs Target the Pathophysiology of Ankylosing Spondylitis

MSC therapy addresses three interconnected pathological processes in AS: chronic autoimmune inflammation at the entheses and synovial joints, pathological new bone formation, and structural degradation of the axial skeleton. The therapeutic rationale is grounded in decades of MSC research in inflammatory arthritis models and early-phase clinical data [5].

1. Immunomodulation — Suppressing the IL-23/IL-17 Axis

The IL-23/IL-17 axis is the central inflammatory pathway in AS. IL-23, produced by activated dendritic cells and macrophages at sites of biomechanical stress (entheses), drives the expansion and activation of Th17 cells, which secrete IL-17A, IL-17F, and IL-22. These cytokines recruit neutrophils, activate osteoclasts, stimulate synovial fibroblasts, and promote the pathological bone remodeling that characterizes AS [6].

MSCs are potent suppressors of Th17-driven inflammation. Through secretion of prostaglandin E2 (PGE2), TGF-β, and indoleamine 2,3-dioxygenase (IDO), MSCs shift the T-cell balance away from pathogenic Th17 cells and toward regulatory T cells (Tregs) that restrain autoimmunity. In co-culture experiments, MSCs reduce IL-17 production by 60–80% and simultaneously expand CD4⁺CD25⁺FoxP3⁺ Treg populations — an immunomodulatory profile that directly counters the central cytokine axis in AS [7].

Importantly, MSC-mediated immunomodulation is context-dependent: MSCs are activated by the inflammatory environment (IFN-γ, TNF-α) to adopt an anti-inflammatory phenotype, meaning they deliver their strongest immunomodulatory effect precisely where and when inflammation is most active — a safety feature that systemic biologics lack.

2. Suppressing Pathological New Bone Formation

The defining structural feature of advanced AS is syndesmophyte formation — the bridging of vertebral bodies by pathological new bone that leads to ankylosis. This process is driven by aberrant activation of the BMP and Wnt signaling pathways in the context of resolving inflammation, creating a paradox where anti-inflammatory treatment alone may not prevent radiographic progression [8].

MSCs may influence the balance between inflammation and ossification. MSCs secrete Dickkopf-1 (DKK-1), an endogenous inhibitor of Wnt signaling, and sclerostin, both of which suppress osteoblast differentiation and activity. In preclinical models of spondyloarthritis, MSC administration reduced the expression of BMP-2 and RUNX2 — master regulators of osteogenesis — at entheseal sites, suggesting a mechanism by which MSCs may decelerate syndesmophyte formation [9].

This is a critical distinction from anti-cytokine biologics. TNF inhibitors effectively suppress inflammation but have not been conclusively shown to arrest radiographic progression in AS. Whether MSC therapy can influence structural outcomes is unknown — preclinical data are encouraging, but long-term radiographic data from human AS trials are not yet available. This remains an open and important research question.

3. Chondroprotection and Tissue Repair at the Axial Joints

The sacroiliac joints, facet joints, and intervertebral discs bear the brunt of inflammatory damage in AS. Chronic synovitis erodes cartilage, and the ensuing repair response — driven by TGF-β and BMPs released from inflamed tissue — produces disorganized fibrocartilage and bone rather than functional restoration of the joint architecture.

MSCs secrete a cocktail of chondroprotective factors — including TGF-β3, BMP-7, and IGF-1 — that promote chondrocyte survival, suppress matrix metalloproteinases (MMP-3, MMP-13) that degrade cartilage, and stimulate the synthesis of type II collagen and aggrecan, the primary structural components of articular cartilage [10]. In intervertebral disc degeneration models, intradiscal MSC injection preserved disc height, improved MRI T2 signal intensity (a marker of hydration and proteoglycan content), and reduced inflammatory cytokine levels in the nucleus pulposus.

Preclinical Evidence: Animal Models of Spondyloarthritis

The preclinical case for MSC therapy in AS draws primarily from two established models: the HLA-B27 transgenic rat (which develops a spondyloarthritis-like phenotype spontaneously) and proteoglycan-induced spondylitis in BALB/c mice. Both recapitulate key features of human AS — sacroiliitis, peripheral arthritis, and enthesitis.

Key findings from spondyloarthritis models:

These data align with a substantial body of preclinical research demonstrating MSC efficacy in related inflammatory arthritis models — collagen-induced arthritis (the RA model), adjuvant arthritis, and antigen-induced arthritis — where MSC therapy consistently reduces synovitis, protects cartilage, and suppresses systemic markers of inflammation [12].

Clinical Evidence: Early-Phase Data in Ankylosing Spondylitis

Important caveat: The clinical evidence for MSC therapy specifically in ankylosing spondylitis is at an early stage. Most data come from small open-label studies and case series. No large randomized controlled trial has been completed. MSC therapy for AS remains investigational and should be understood as complementary to — not a replacement for — standard rheumatologic care including biologics.

Direct AS evidence is limited but directionally consistent. A 2022 open-label study from China enrolled 24 patients with active AS (BASDAI ≥ 4 despite NSAID therapy) who received 3 intravenous infusions of allogeneic umbilical cord-derived MSCs (1 × 10⁶ cells/kg) at 4-week intervals. At 6 months, the mean BASDAI score decreased from 5.8 to 2.9 (p < 0.001), the ASDAS-CRP fell from 3.2 to 1.7, and the mean BASFI (functional index) improved from 5.2 to 3.1 [13]. CRP levels declined significantly, and no serious adverse events were reported.

A 2024 case series from a Thai center reported 8 biologic-refractory AS patients (failed ≥2 TNF inhibitors) who received UC-MSC therapy (2 infusions, 1.5 × 10⁶ cells/kg each, 6 weeks apart). At 12-month follow-up, 6 of 8 patients achieved a clinically important improvement (BASDAI reduction ≥ 2 points), and 4 achieved ASDAS low disease activity. Spinal mobility measures (modified Schober test, chest expansion) showed modest but consistent improvements [14].

Extrapolation from rheumatoid arthritis. The evidence base for MSC therapy in inflammatory arthritis is far more developed in RA. A meta-analysis of 12 clinical trials (n = 543) found that MSC therapy significantly reduced DAS28 scores (weighted mean difference −1.63, p < 0.001) and improved HAQ disability scores across multiple studies with an excellent safety profile [15]. While RA and AS differ in their target joints and pathogenic pathways, they share core features — chronic synovial inflammation, T-cell dysregulation, and a relapsing-remitting course — that make the RA data cautiously informative for AS.

5.8 → 2.9 Mean BASDAI reduction (6 months, open-label AS study, n=24)
6/8 Biologic-refractory AS patients improved (case series, 2024)
−1.63 Pooled DAS28 improvement in RA MSC trials (meta-analysis)
0 Serious adverse events in published AS MSC studies

Treatment Protocol Considerations for AS

MSC therapy for AS is conceptualized as an adjunctive immunomodulatory intervention — not a replacement for NSAIDs, biologics, or physiotherapy. The strongest theoretical rationale is for patients with active AS who have inadequate response to or intolerance of biologics, or who experience ongoing symptoms and elevated inflammatory markers despite biologic therapy.

Key protocol considerations:

Safety and Limitations

MSC therapy has an excellent safety track record, but specific considerations apply in the AS context. A 2024 systematic review of MSC safety across 3,000+ patients found no increased risk of malignancy, thromboembolism, or serious infection compared to controls [16].

However, the following limitations must be acknowledged:

VELAR Center's Approach to Ankylosing Spondylitis

At VELAR Center in Bangkok, we evaluate each AS patient individually. Our clinical team reviews the complete rheumatologic history — disease duration, current and prior medications (NSAIDs, DMARDs, biologics), BASDAI/BASFI scores, CRP and ESR trends, and available imaging (X-ray, MRI sacroiliac joints and spine) — before making a recommendation. The strongest candidates for adjunctive MSC therapy are patients with persistently active AS (BASDAI ≥ 4) despite optimized biologic therapy, or those who have contraindications to or have exhausted available biologics.

Our protocols are grounded in the published evidence and individualized to each patient's disease activity and treatment goals. We use umbilical cord-derived MSCs manufactured under ISO 9001 and ISO/IEC 17025 quality systems, with ≥95% MSC marker expression (CD73⁺, CD90⁺, CD105⁺), multi-pathogen sterility testing, and post-thaw viability consistently exceeding 90%. Every batch is independently verified before release — the same quality infrastructure that supports our work across rheumatologic, orthopedic, and neurodegenerative indications.

Medical tourism note: For international patients traveling to Bangkok for MSC therapy, our patient coordinators can assist with visa documentation, airport transfer, and accommodation near the clinic. We recommend a stay of 5–7 days for the initial evaluation and first infusion, with follow-up infusions scheduled at 3–6 week intervals. Telemedicine follow-up is available between visits. We collaborate with your local rheumatologist to ensure continuity of care.

Frequently Asked Questions

Can stem cell therapy cure ankylosing spondylitis?

No. MSC therapy is not a cure for AS. It is an investigational adjunctive treatment that aims to reduce disease activity, improve spinal mobility, and potentially slow structural progression. The goal is better disease control, not a cure — even the most effective biologics do not cure AS.

Can I receive MSC therapy while on biologics for AS?

In published protocols, MSC therapy has been used both during biologic holidays and concurrently with ongoing biologic therapy. The optimal approach has not been formally studied. At VELAR Center, we coordinate directly with your treating rheumatologist to determine the safest and most appropriate integration of MSC therapy into your existing treatment regimen.

How much does stem cell therapy for ankylosing spondylitis cost in Thailand?

A typical course of MSC therapy for AS at VELAR Center ranges from approximately USD 10,000–20,000 depending on the number of cells and infusions recommended after clinical evaluation. This is not covered by insurance, and patients should budget for travel and accommodation separately.

What improvements can I realistically expect?

Based on the limited published data, patients may experience reduced inflammatory back pain, decreased morning stiffness, improved spinal mobility, and lower CRP levels. Not all patients respond — published response rates in small series range from 50–75%. The most realistic expectation is meaningful symptom improvement rather than complete remission.

How long do the effects of MSC therapy last in AS?

Published follow-up in AS studies is limited to 6–12 months. In RA literature, where longer follow-up exists, clinical benefits typically persist for 6–18 months after a treatment course, with gradual decline thereafter. Maintenance infusions may extend the duration of benefit, though this is not yet supported by controlled data.

Is MSC therapy safe for AS patients with uveitis or other extra-articular manifestations?

MSC therapy has not been specifically studied in AS patients with active uveitis. The immunomodulatory effects of MSCs are systemic and could theoretically benefit extra-articular inflammation, but this is speculative. Patients with active uveitis require continued ophthalmologic management and should discuss MSC therapy with both their rheumatologist and ophthalmologist.

References

  1. Sieper J, Poddubnyy D. Axial spondyloarthritis. The Lancet. 2017;390(10089):73-84. doi:10.1016/S0140-6736(16)31591-4 ↩
  2. Braun J, Sieper J. Ankylosing spondylitis. The Lancet. 2007;369(9570):1379-1390. doi:10.1016/S0140-6736(07)60635-7 ↩
  3. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Annals of the Rheumatic Diseases. 2017;76(6):978-991. doi:10.1136/annrheumdis-2016-210770 ↩
  4. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 ↩
  5. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13(4):392-402. doi:10.1016/j.stem.2013.09.006 ↩
  6. Smith JA, Colbert RA. The IL-23/IL-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis & Rheumatology. 2014;66(2):231-241. doi:10.1002/art.38291 ↩
  7. Ghannam S, Pène J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Journal of Immunology. 2010;185(1):302-312. doi:10.4049/jimmunol.0902007 ↩
  8. Lories RJ, Haroon N. Bone formation in axial spondyloarthritis. Best Practice & Research Clinical Rheumatology. 2017;31(6):816-829. doi:10.1016/j.berh.2018.07.006 ↩
  9. Xie Z, Yu S, He C, et al. Mesenchymal stem cells inhibit pathologic new bone formation in ankylosing spondylitis via DKK-1 mediated Wnt signaling suppression. Stem Cells Translational Medicine. 2019;8(8):831-843. doi:10.1002/sctm.18-0268 ↩
  10. Richardson SM, Kalamegam G, Pushparaj PN, et al. Mesenchymal stem cells in regenerative medicine: focus on the intervertebral disc. Stem Cells International. 2016;2016:8012164. doi:10.1155/2016/8012164 ↩
  11. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends in Immunology. 2012;33(3):136-143. doi:10.1016/j.it.2011.11.004 ↩
  12. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis & Rheumatism. 2009;60(4):1006-1019. doi:10.1002/art.24405 ↩
  13. Li A, Tao Y, Kong D, et al. Allogeneic umbilical cord-derived mesenchymal stem cell therapy for patients with active ankylosing spondylitis: an open-label pilot study. Frontiers in Immunology. 2022;13:901973. doi:10.3389/fimmu.2022.901973 ↩
  14. Phonphok P, Wattanawarangkoon S, Koonrungsesomboon N. Umbilical cord-derived mesenchymal stem cell therapy in biologic-refractory ankylosing spondylitis: a single-center case series. Asian Pacific Journal of Allergy and Immunology. 2024;42(1):58-66. doi:10.12932/AP-040823-1679 ↩
  15. Wang L, Huang S, Li S, et al. Efficacy and safety of mesenchymal stem cell therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis. Frontiers in Immunology. 2021;12:737228. doi:10.3389/fimmu.2021.737228 ↩
  16. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 ↩